Eupraxia Pharmaceuticals Inc.

TSX:EPRX Stock Report

Market Cap: CA$154.2m

Eupraxia Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:EPRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Sep 24BuyCA$6,988Michael WilminkIndividual1,900CA$3.71
28 Jun 24BuyCA$51,800John MontalbanoIndividual14,800CA$3.50
17 Jun 24BuyCA$4,024Michael WilminkIndividual1,100CA$3.66
11 Jun 24BuyCA$3,096Michael WilminkIndividual800CA$3.87
07 Jun 24BuyCA$3,755Michael WilminkIndividual1,000CA$3.75
10 May 24BuyCA$2,623Michael WilminkIndividual640CA$4.10

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EPRX?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,864,8685.24%
Hedge Funds2,784,0497.82%
Individual Insiders7,263,77420.4%
General Public23,709,86266.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.7%.

Top Shareholders

Top 23 shareholders own 33.44% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.68%
Robert Disbrow
3,092,500CA$13.4m0%no data
7.82%
Manchester Management Company, LLC
2,784,049CA$12.1m0%21.77%
4.21%
Joseph Freedman
1,501,200CA$6.5m0%no data
3.92%
Scotiabank Global Banking and Markets, Asset Management Division
1,396,281CA$6.0m2.14%0.02%
3.4%
John Montalbano
1,212,466CA$5.2m0%no data
1.89%
James Helliwell
674,012CA$2.9m0%no data
0.96%
Paul Geyer
340,346CA$1.5m0%no data
0.63%
Michael Wilmink
224,865CA$973.7k0.85%no data
0.41%
RBC Dominion Securities Inc., Asset Management Arm
146,287CA$633.4k3.94%no data
0.35%
RBC Private Counsel (USA) Inc.
125,000CA$541.2k0%0.01%
0.32%
Bruce Cousins
114,286CA$494.9k0%no data
0.18%
Ninepoint Partners LP
65,900CA$285.4k0%0.01%
0.14%
BMO Asset Management Corp.
49,250CA$213.3k0%no data
0.13%
Amanda Malone
46,343CA$200.7k0%no data
0.097%
Goldman Sachs Group, Investment Banking and Securities Investments
34,500CA$149.4k0%no data
0.093%
UBS Asset Management AG
33,000CA$142.9k11.5%no data
0.076%
Paul Brennan
27,200CA$117.8k0%no data
0.039%
Richard Glickman
13,930CA$60.3k0%no data
0.036%
180 Wealth Advisors, LLC
13,000CA$56.3k0%0.01%
0.024%
Simon Pimstone
8,626CA$37.3k0%no data
0.022%
Mark Kowalski
8,000CA$34.6k0%no data
0.0042%
Toronto-Dominion Bank, Banking Investments
1,500CA$6.5k0%no data
0.00042%
National Bank Investments Inc.
150CA$647.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eupraxia Pharmaceuticals Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthCanaccord Genuity
Gary NachmanRaymond James & Associates
Rahul SarugaserRaymond James Ltd.